Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition for treating ovarian cancer and a preparation method thereof

A composition and technology for ovarian cancer, applied in the field of tumor drugs, can solve problems such as the appearance of toxic and side effects of chemotherapy drugs in cancer cells of patients, and achieve the effects of adjuvant treatment of ovarian cancer, good targeting and safety, and broad application prospects.

Inactive Publication Date: 2019-01-15
BENGBU MEDICAL COLLEGE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical treatment of ovarian cancer generally adopts a comprehensive treatment method combining surgery and chemotherapy. However, as the patient's treatment continues, the drug resistance of the patient's cancer cells and the side effects of chemotherapy drugs are gradually emerging.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some of the embodiments of the present invention, but not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.

[0010] The invention provides a technical solution: a pharmaceutical composition for treating ovarian cancer, the composition includes plasmid DNA non-viral vector, IL-2 interleukin, p53 tumor suppressor gene and secreted leukocyte protease inhibitor SLPI.

[0011] Wherein, the plasmid DNA non-viral vector is liposome DNA co-constructed by dioleoyltrimethylamide propane, 1,2-dioleoyl-3-phosphatidylethanolamine and cholesterol.

[0012] The present invention also provides a preparation method of a pharmaceutical composition for treat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating ovarian cancer in the technical field of tumor medicine and a preparation method thereof, wherein the composition comprises a plasmidDNA non-viral vector, IL-2 interleukin , a p53 tumor suppressor gene and a secretory leukocyte protease inhibitor SLPI. The non-viral vector is adopted, hydrophilic or hydrophobic polyvalent cationicpolymers are utilized to agglomerate recombinant plasmids or reactive oligonucleotides to form particles for endocytosis. The composition has good targeting and safety, can induce the immune signal reaction of the organism, reduce the tumorigenicity of the ovarian cancer cell, and inhibit the growth of the tumor. As that cytokine gene is transfect into the ovarian cancer cell, the immunogenicity of the ovarian cancer cell is improved, the anti-tumor immune function of the organism is activated, the purpose of assisting treatment of the ovarian cancer is achieved, and the method has a broad application prospect.

Description

technical field [0001] The invention discloses a pharmaceutical composition for treating ovarian cancer and a preparation method thereof, specifically in the technical field of tumor medicine. Background technique [0002] Ovarian cancer is one of the common malignant tumors of female reproductive organs, accounting for about 20% of female reproductive tract malignant tumors, and its incidence rate ranks third after cervical cancer and uterine body cancer. Ovarian cancer has no obvious early-onset specific symptoms, and it is difficult to screen. Generally, two-thirds of it is in the middle and late stage when it is discovered. At present, the clinical treatment of ovarian cancer generally adopts a comprehensive treatment method combining surgery and chemotherapy, but as the patient's treatment continues, the drug resistance of the patient's cancer cells and the side effects of chemotherapy drugs gradually appear. Therefore, we propose a pharmaceutical composition for treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K38/20A61K45/06A61K47/18A61K47/24A61K47/28A61P35/00
CPCA61K38/2013A61K45/06A61K47/18A61K47/24A61K47/28A61K48/0058A61P35/00
Inventor 梁猛胡柯
Owner BENGBU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com